A5065240152- Treatment of Major Depression
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Mental Health Research Topics
- Electroconvulsive Therapy Studies
- Intensive Care Unit Cognitive Disorders
- Cardiac Health and Mental Health
- Diet and metabolism studies
- Suicide and Self-Harm Studies
- Psychiatric care and mental health services
- Migraine and Headache Studies
- Mental Health and Patient Involvement
- Tryptophan and brain disorders
- Mental Health and Psychiatry
- Schizophrenia research and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Anesthesia and Sedative Agents
Lundbeck (Denmark)
2021-2024
Patients with major depressive disorder (MDD) often experience comorbid anxiety symptoms. Vortioxetine has demonstrated efficacy in treating symptoms patients MDD; however, and tolerability have not been assessed across the entire approved dosage range. The of vortioxetine 5–20 mg/day were MDD high levels (Hamilton Anxiety Rating Scale [HAM-A] total score ≥ 20) using pooled data from four randomized, fixed-dose, placebo-controlled studies (n = 842). Data a double-blind study 10–20 versus...
Vortioxetine has demonstrated dose-dependent efficacy in patients with major depressive disorder (MDD), the greatest effect observed vortioxetine 20 mg/day. This analysis further explored clinical relevance of more rapid and greater improvement symptoms mg/day vs 10 Analysis pooled data from six short-term (8-week), randomized, placebo-controlled, fixed-dose studies MDD (N = 2620). Symptomatic response (≥50% decrease Montgomery-Åsberg Depression Rating Scale [MADRS] total score), sustained...
Background Vortioxetine has demonstrated procognitive effects in patients with major depressive disorder (MDD). We assessed the effectiveness and safety of vortioxetine a cohort MDD comorbid Alzheimer’s disease participating large post-marketing surveillance study South Korea. Methods Subgroup analysis 6-month, prospective, multicenter, non-interventional outpatients pre-baseline diagnosis receiving routine care settings ( n = 207). Patients were at baseline after 8 weeks; subset was also 24...
Background: Data demonstrating the real-world, long-term effectiveness of vortioxetine in elderly patients with major depressive disorder (MDD) are clinically useful to confirm findings from randomized trials. Methods: RELIEVE was a multinational, 24-week, observational, prospective study outpatients MDD initiating treatment routine care settings (NCT03555136). Here, we report data subgroup 130 aged ⩾ 65 years. The primary outcome changed baseline patient functioning assessed using Sheehan...
Abstract Background For patients with schizophrenia, relapse is a recurring feature of disease progression, often resulting in substantial negative impacts for the individual. Although patient’s history (specifically number prior relapses) has been identified as strong risk factor future relapse, this relationship not yet meticulously quantified. The objective study was to use real-world data from Sweden quantify time schizophrenia relapses. Methods Data Swedish National Patient Register and...
The Motivation and Energy Inventory (MEI) is a patient-reported scale for assessment of the impact mental/cognitive energy, social motivation, physical energy on daily functioning in patients with major depressive disorder (MDD). This analysis was undertaken to establish clinically relevant response threshold MEI MDD receiving antidepressant treatment. Patients experiencing inadequate emotional blunting selective serotonin reuptake inhibitor or serotonin-noradrenaline monotherapy (adequate...
Objective Vortioxetine has demonstrated safety and efficacy in improving symptoms of major depressive disorder (MDD), including overall functioning real-world settings. This is the first study a real-life clinical setting India to evaluate effectiveness vortioxetine patients with MDD.
Objectives: To qualitatively identify evidence-based literature related to the daily burden and unmet treatment psychosocial needs of patients with cluster headache (CH). Methods: A search was conducted through October 20, 2020 across MEDLINE, EMBASE, CINAHL, PsychInfo databases exploring quality life (QoL) disease in adults CH. The restricted full-text reports peer-reviewed journals. Methodologic assessed using Critical Skills Appraisal Program. Results: From 11 identified publications, QoL...
Background: Generalized anxiety disorder (GAD) is commonly co-morbid with major depressive (MDD) and associated greater functional impairment poorer treatment outcomes than MDD alone. However, studies on drugs for depression in patients GAD are limited. Aims: To examine the effectiveness of vortioxetine a subgroup analysis real-world RELIEVE study. Methods: The included outpatients diagnosed who initiated at their physician’s discretion 24-week, observational Primary outcome was patient...
Patients with major depressive disorder (MDD) experience symptoms such as anhedonia well cognitive dysfunction which can subsequently impair their work performance.
Background: Vortioxetine is efficacious and well tolerated in patients with major depressive disorder (MDD) available as an immediate-release tablet oral drop solution. The solution may offer clinical benefits versus a tablet, such the reduced risk of nausea, personalised dosing ease administration. Aims: To investigate bioequivalence vortioxetine 20 mg/mL mg tablet. Methods: Healthy adults were randomised 1:1 to receive or after fasting on days 1 29 open-label, single-centre, single-dose...